Effects of Open-Label Lisdexamfetamine Dimesylate on Self-Reported Quality of Life in Adults with ADHD
Authors:
- Matthew BramsMBMatthew Brams
- John GiblinJGJohn Giblin
- Maria GasiorMGMaria Gasior
- Joseph GaoJGJoseph Gao
- Timothy WigalTWTimothy Wigal
- 1 May 2011
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 123 (3) , 99-108
Abstract
To assess improvements in quality of life measurements during the open-label portion of a trial examining duration of efficacy of lisdexamfetamine dimesylate in a simulated adult workplace environment. A 4-week, open-label, dose-optimization phase followed by a randomized, double-blind, multicenter, placebo-controlled, 2-way crossover phase to evaluate safety and efficacy of lisdexamfetamine dimesylate in the adult workplace environment was conducted. Clinical assessments included the ADHD Impact Module for Adults (AIM-A) to assess the effect of lisdexamfetamine dimesylate on perception of quality of life and the Clinical Global Impressions-Severity/Improvement to assess symptom severity at baseline and improvement over time. Safety assessments included physical examination, treatment-emergent adverse events, vital signs, and electrocardiogram measurements. Questions 1 and 4 of the AIM-A suggest improvement from baseline in overall quality of life at week 4 with lisdexamfetamine dimesylate treatment. Post-hoc analysis revealed no significant differences attributable to either age or sex. Overall responses to questions 2 and 3, which related to overall life goals, did not change in a majority of participants during the 4-week open-label phase of this study. For all lisdexamfetamine dimesylate doses combined, treatment-emergent adverse events occurring in ≥ 5% of participants during the dose-optimization phase were decreased appetite (36.6%), dry mouth (30.3%), headache (19.7%), insomnia (18.3%), upper respiratory tract infection (9.9%), irritability (8.5%), nausea (7.7%), anxiety (5.6%), and feeling jittery (5.6%). At the end of the dose-optimization phase, lisdexamfetamine dimesylate treatment suggested quality of life improvements in adults with ADHD, with a safety profile consistent with long-acting stimulant use.Keywords
This publication has 20 references indexed in Scilit:
- Moderators and Mediators of Symptoms and Quality of Life Outcomes in an Open-Label Study of Adults Treated for Attention-Deficit/Hyperactivity DisorderThe Journal of Clinical Psychiatry, 2010
- Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment designBehavioral and Brain Functions, 2010
- Measuring Methylphenidate Response in Attention-Deficit/Hyperactvity Disorder: How Are Laboratory Classroom-Based Measures Related to Parent Ratings?Journal of Child and Adolescent Psychopharmacology, 2009
- Effects of Clonidine and Methylphenidate on Family Quality of Life in Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2009
- The quality of life of children with attention deficit/hyperactivity disorder: a systematic reviewEuropean Child & Adolescent Psychiatry, 2009
- Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity DisorderJournal of Clinical Psychopharmacology, 2009
- Reliability, Validity, and Utility of Instruments for Self-Report and Informant Report Concerning Symptoms of ADHD in Adult PatientsJournal of Attention Disorders, 2008
- Monitoring Quality of Life in Adults With ADHDJournal of Attention Disorders, 2007
- The Consequences of Attention-Deficit/Hyperactivity Disorder in AdultsJournal of Psychiatric Practice, 2007
- The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder.Journal of Abnormal Psychology, 2002